Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | PDE4A | P27815 | 14/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409415 | 0.98 | CYP1A2 (0.73) | CYP1A2GAAPDE4ASMN1; SMN2PDE7A | |
| SCHEMBL185651 | 0.82 | CYP1A2 (0.71) | CYP1A2GAAPDE4APDE7AALDH1A1 | |
| SCHEMBL20340406 | 0.82 | CYP1A2 (0.71) | CYP1A2GAAPDE4ASMN1; SMN2PDE7A | |
| SCHEMBL15647965 | 0.82 | CYP1A2 (0.71) | CYP1A2GAAPDE4ASMN1; SMN2PDE7A | |
| SCHEMBL27003065 | 0.82 | CYP1A2 (0.71) | CYP1A2GAAPDE4ASMN1; SMN2PDE7A | |
| SCHEMBL2534556 | 0.81 | CYP1A2 (0.70) | CYP1A2GAAPDE4ASMN1; SMN2PDE7A | |
| SCHEMBL1715548 | 0.80 | CYP1A2 (0.73) | CYP1A2GAAPDE4ASMN1; SMN2PDE7A | |
| SCHEMBL2538688 | 0.79 | CYP1A2 (0.72) | CYP1A2GAAPDE4ASMN1; SMN2PDE7A | |
| SCHEMBL18961812 | 0.78 | GAA (1.00) | CYP1A2GAAPDE4APDE7AALDH1A1 | |
| SCHEMBL2126554 | 0.76 | CYP1A2 (0.68) | CYP1A2GAAPDE4ASMN1; SMN2PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420682-B2 | N-phenylacetamide derivatives, which inhibit the enzyme SOAT-1, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20120021017-A1 | N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-2401259-A1 | NOVEL N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | Galderma Research & Development (FR) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097464-A1 | NOVEL N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021017-A1 | N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | SOAT1, SOAT2, NAT1 | CYP1A2 223/4885GAA 96/4885PDE4A 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.